

eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) e-learning

Session 1.0: Introduction

Version 5.5



Overview

The European Medicines Agency (EMA) offers a self-paced e-learning training on the submission of authorised and un-authorised (referred to in the XEVMPD as 'development') medicinal product data in the XEVMPD:

- Authorised medicinal product (AMP) data is submitted in the XEVMPD (also referred to as 'Article 57 database') by marketing authorisation holders;
- Development medicinal product (DMP) data is submitted in the XEVMPD by sponsors of clinical trials.

How to participate in the e-learning training course

Users from MAH organisations, sponsor organisations, third-party service providers and/or national competent authorities should review the following documentation as part of their training:

- XEVMPD e-learning presentations;
- Step-by-step quides;
- <u>eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB)</u> <u>user manual;</u>
- <u>Chapter 3.II: Extended EudraVigilance product report message (XEVPRM) user guidance</u>, providing detailed guidance on the submission of AMPs, and/or
- <u>Guidance on the electronic submission of information on investigational medicinal products</u> <u>for human use in the Extended EudraVigilance medicinal product dictionary (XEVMPD)</u>, providing detailed guidance on the submission of DMPs.

Learning Objectives (1/3)

Once the XEVMPD e-learning training is competed, users should be able to:

- Understand the concepts related to the electronic submission of information on authorised and un-authorised medicines in the EU/EEA, i.e.:
 - Describe the eXtended EudraVigilance product report message (XEVPRM) format and the data elements required each product type,
 - Become familiar with practical examples of different types of medicinal products,
 - Get hands-on experience in working with the XEVMPD data entry tool (EVWEB);

Learning Objectives (2/3)

- Understand the legal requirements for marketing authorisation holders (MAHs) to comply with the provisions set out in Article 57(2) of Regulation (EC) 726/2004, as amended by Regulation (EU) 1235/2010 and Regulation (EU) 1027/2012;
- Understand the requirements for sponsors of clinical trials as outlined in the Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use' ('CT-3') (OJ 2011/C 172/01);

Learning Objectives (3/3)

- Understand the controlled vocabularies and terminologies to be used during the submission process;
- Use the XEVMPD data entry tool (EVWEB) for the electronic submission and maintenance of different types of medicinal products;
- Explain the data structure of the XEVMPD for data entry and data retrieval;
- Understand the importance of the XEVMPD to support the pharmacovigilance activities in the EU/EEA.

XEVMPD knowledge evaluation

Once the e-learning course is completed, users can perform an XEVMPD **knowledge evaluation** to obtain a 'Notification of successful completion of the XEVMPD knowledge evaluation' if a passing score is received

'Notification of successful completion of the XEVMPD knowledge evaluation' is required from at least one user during the organisation's registration process with EudraVigilance:

- To receive the notification of successful completion of the XEVMPD knowledge evaluation for the **submission of authorised medicinal product data** in the XEVMPD, participants will be required to demonstrate their knowledge on the submission of AMPs;
- To receive the notification of successful completion of the XEVMPD knowledge evaluation for the **submission of un-authorized (i.e., development) medicinal product data** in the XEVMPD, participants will be required to demonstrate their knowledge on the submission of DMPs.

XEVMPD knowledge evaluation registration

To register for the XEVMPD e-learning knowledge evaluation, an **XEVMPD e-learning** registration request must be submitted via the EMA Service Desk Portal:

 Users should clarify in their request if they wish to register for the knowledge evaluation of the submission of AMP and/or DMP data.

Following their registration, users will be provided with a User ID and password, allowing them to access the **XEVMPD test environment (XCOMP)** to practise and to complete the XEVMPD e-learning knowledge evaluation:

- The credentials are valid for four weeks since they were provided to the user;
- Any possible subsequent attempts must be performed during this time frame.

XEVMPD knowledge evaluation details (1/2)

The knowledge evaluation consist of two parts:

- Part I: Multiple choice questionnaire:
 - Questions summarising the understanding of the XEVPRM and/or XEVMPD definitions and concepts,
 - Each correct answer is assigned one point,
 - If an incorrect answer is provided, no point is assigned.
- Part II: Product report exam case(s):
 - Based on the provided information, users are required to enter authorised and/or un-authorised medicinal product data in the XEVMPD using EVWEB;
 - Points are assigned for each correctly populated field;
 - Points are deducted for major mistakes.



XEVMPD knowledge evaluation details (2/2)

- The pass rate for <u>each part</u> of the knowledge evaluation is 80%.
- Participants have three attempts to pass each section of the knowledge evaluation.

Registration with EudraVigilance

- Detailed steps and definitions are described on the "Registration with EudraVigilance" webpages, section <u>'EudraVigilance: How to register' webpage</u>.
- **EudraVigilance related questions** should be submitted via the 'Ask a question' form in the EMA Service Desk Portal.
- **EudraVigilance Registration queries** should be submitted via the <u>`EudraVigilance Registration queries' form</u> in the <u>EMA Service Desk Portal</u>.

Contact details

- Questions related to the submission of authorised and un-authorised medicinal product data in the Article 57 database/XEVMPD should be submitted using the <u>'Ask a question' form</u> in the <u>EMA Service Desk Portal</u>
- Technical issues should be reported using the via the <u>'Report an Issue' form</u> in the <u>EMA</u>
 Service Desk Portal
- Requests for XEVMPD/Art57 services should be submitted via the <u>'Request XEVMPD/Art.57 Services' form in the EMA Service Desk Portal</u>

Reference documents

- Further information related to product data submissions in the Article 57 database/XEVMPD can be found on the:
 - <u>'Data submission on authorised medicines (Article 57)' webpage;</u>
 - 'Guidance documents' webpage;
 - '<u>Data submission on investigational medicines: guidance for clinical trial sponsors' webpage</u>.